Table 1.

Patient characteristics

Patient	Prestudy HAART regimen	Nadir CD4+ T cells per mm3 prior to HAART*	CD4+ T cells per mm3 prior to SIT	Plasma HIV RNA prior to HAART†	Months on HAART prior to study
301	d4T, 3TC, SQV	262	727	307,000	11
302	d4T, ddC, IDV	383	1,286	16,900	35
303	AZT, 3TC, IDV	426	1,196	61,000	11
304	d4T, 3TC, IDV, RTV	465	913	87,489	7
305	AZT, 3TC, ABV, NVP	464	548	60,426	13
306	d4T, 3TC, EFV	484	1,375	59,000	43
307	3TC, NFV, EFV	260	695	30,234	9
308	d4T, 3TC, IDV, RTV	386	553	15,771	15
309	d4T, 3TC, IDV, RTV	574	813	5,370	14
310	d4T, 3TC, EFV	254	758	51,400	31
Median		406	786	55,200	13.5

3TC, lamivudine; SQV, saquinavir; ddC, zalcitabine; IDV, indinavir; AZT, zidovudine; RTV, ritonavir; ABV, abacavir; NVP, nevirapine; EFV, efavirenz; d4T, stavudine. 

^*Lowest documented CD4⁺ T cells per mm³. 

^† Highest documented HIV RNA copies per ml.